SCHEMBL6832063

SCHEMBL6832063

CCCCS(=O)(=O)NCCC(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.45
GPR84 Q9NQS5 7/20 0.43
PPARG P37231 7/20 0.43
PPARD Q03181 7/20 0.43
PPARA Q07869 7/20 0.43
HDAC11 Q96DB2 5/20 0.43
TSHR P16473 4/20 0.43
PTPN1 P18031 3/20 0.43
ALDH1A1 P00352 2/20 0.43
TLR2 O60603 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
FABP4 P15090 2/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
SLC22A8 Q8TCC7 1/20 0.43
MEN1 O00255 1/20 0.43
ESR1 P03372 1/20 0.43
ALOX15 P16050 1/20 0.43
PDE4A P27815 1/20 0.43
KMT2A Q03164 1/20 0.43
PDE3A Q14432 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10895115 0.94 RELA (0.49) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL6578156 0.93 RELA (0.51) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL7824985 0.93 RELA (0.51) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL31522322 0.87 GPR84 (0.53) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL10695605 0.82 CA12 (0.39) AKR1B1ALDH1A1ALOX15CA12CA14
SCHEMBL6578168 0.81 PLA2G2A (0.51) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL9266535 0.81 ALDH1A1 (0.44) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL10897013 0.80 MMP8 (0.44) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL608990 0.79 CA1 (0.61) PPARAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL5689488 0.79 CA1 (0.52) PPARAALDH1A1HSD17B10CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1411926-A1 INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES MERCK PATENT GmbH (DE) 2004-04-28 EP claimed
WO-2003013511-A1 INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES MERCK PATENT GMBH (DE) 2003-02-20 WO claimed
EP-0944619-A1 NOVEL INTEGRIN RECEPTOR ANTAGONISTS Du Pont Pharmaceuticals Company (US) 1999-09-29 EP claimed
WO-1998023608-A1 NOVEL INTEGRIN RECEPTOR ANTAGONISTS DUPONT PHARMACEUTICALS COMPANY (US) 1998-06-04 WO claimed
EP-0951295-A4 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ANGIOGENESIS SCRIPPS RESEARCH INST (US) 2000-07-26 EP disclosed
EP-0951295-A1 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ANGIOGENESIS The Scripps Research Institute (US) 1999-10-27 EP disclosed
EP-0944619-A1 NOVEL INTEGRIN RECEPTOR ANTAGONISTS Du Pont Pharmaceuticals Company (US) 1999-09-29 EP disclosed
WO-1998023608-A1 NOVEL INTEGRIN RECEPTOR ANTAGONISTS DUPONT PHARMACEUTICALS COMPANY (US) 1998-06-04 WO disclosed
WO-1997045137-A1 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ANGIOGENESIS THE SCRIPPS RESEARCH INSTITUTE (US) 1997-12-04 WO disclosed